Chronic subdural hematoma (CSDH), a prevalent neurosurgical condition, especially among the elderly, is on the rise due to an aging population and increased use of blood-thinning medications. With an annual incidence ranging from 1.7 to 20.6 per 100,000 people, CSDH is expected to become the most common condition requiring cranial surgery by 2030. Despite its prevalence, treatment options have been limited, largely due to an incomplete understanding of its underlying causes. This review aims to provide a comprehensive overview of CSDH, covering its epidemiology, pathogenesis, diagnosis, and evolving treatment strategies, with a special focus on the emerging role of middle meningeal artery embolization (MMAE).
The Aging Brain: A Growing Concern
CSDH is the second most common neurosurgical disease, with rates as high as 127.1 per 100,000 among those over 80 years old. The increasing use of anticoagulants and antiplatelet medications, combined with the higher risk of falls in older adults, contributes to the growing burden of CSDH. Recurrence is a significant challenge, affecting approximately 10% of surgically treated patients, with advanced age, anticoagulant use, male gender, and poor postoperative brain re-expansion being key risk factors.
Unraveling the Complex Pathogenesis
The development of CSDH involves a complex interplay of traumatic, inflammatory, and angiogenic mechanisms. While traditional models focused on bridging vein rupture, recent studies suggest this may not fully explain non-traumatic cases. Current evidence highlights the role of injury to the dural border cell layer, leading to inflammation, fibrinolytic dysregulation, and the formation of new blood vessels (neovascularization). Key mediators, such as vascular endothelial growth factor (VEGF) and pro-inflammatory cytokines (e.g., IL-6, IL-8), drive the formation of membranes and recurrent microbleeds from fragile neovessels. This self-perpetuating cycle of inflammation and angiogenesis underlies the chronic nature and recurrence of CSDH.
Diagnosis: Unlocking the Secrets
Computed tomography (CT) is the primary imaging modality for CSDH, typically revealing crescent-shaped collections of blood with varying densities. However, CT has limitations in detecting small or less dense hematomas and in characterizing internal structures. Magnetic resonance imaging (MRI) offers superior soft-tissue resolution, allowing better visualization of septations and membrane structures, which can help predict recurrence risk. Advanced MRI techniques, such as diffusion-weighted imaging, are increasingly used to assess hematoma maturity and guide treatment planning.
Treatment Strategies: A Multifaceted Approach
Surgical Interventions:
Twist-drill craniostomy (TDC): A minimally invasive technique suitable for bedside procedures, but associated with higher recurrence and risks of cortical injury.
Burr-hole craniostomy (BHC): The most widely used method, offering high efficacy and low morbidity, though recurrence remains a concern. Ongoing debates surround technical variations, including the type of irrigation fluid, patient positioning, and drainage location (subdural vs. subgaleal).
Craniotomy: Reserved for complex, recurrent, or organized hematomas, but carries higher complication and mortality rates.
Endoscopic-assisted evacuation: Allows direct visualization and complete membrane removal, potentially reducing recurrence, but requires expertise and may prolong operative time.
Middle Meningeal Artery Embolization (MMAE):
MMAE has emerged as a promising minimally invasive intervention that targets the neovascularization responsible for CSDH persistence and recurrence. By blocking the blood supply to the hematoma membranes through embolization of the middle meningeal artery, MMAE promotes resolution. It can be used as a primary treatment or as an adjunct to surgery, especially in high-risk patients on anticoagulants or with recurrent CSDH. Studies report low recurrence rates of around 4.3% with MMAE, but its role in acute symptom relief is limited.
Non-surgical and Pharmacological Management:
For asymptomatic or high-risk patients, conservative management is an option. Pharmacological therapies aim to modulate inflammation and angiogenesis:
Atorvastatin: Reduces inflammation and promotes vascular repair, showing promise in reducing hematoma volume and recurrence.
Corticosteroids: Potent anti-inflammatory agents, but with mixed evidence of efficacy and significant side effects associated with long-term use.
Tranexamic acid (TXA): An antifibrinolytic agent that may reduce rebleeding, but its safety in elderly patients requires further study.
ACE Inhibitors: Controversial due to conflicting data on their impact on angiogenesis and recurrence.
Herbal Medicine: Preliminary studies suggest agents like Goreisan may reduce recurrence, but clinical evidence is limited.
Looking Ahead: Future Directions
Despite advancements, CSDH management is hindered by a lack of standardized protocols and limited high-quality evidence. Future research should focus on clarifying pathophysiological mechanisms to develop targeted therapies, validating the efficacy and safety of MMAE through randomized trials, establishing consensus on surgical techniques and perioperative care, and exploring combination therapies, such as statins with corticosteroids or MMAE with minimally invasive surgery.
Conclusion: A Dynamic Field in Neurosurgery
CSDH is a rapidly evolving field in neurosurgery. While surgical evacuation remains the primary treatment, the high recurrence and complication rates highlight the need for improved strategies. MMAE represents a paradigm shift, offering a targeted, minimally invasive alternative. Pharmacological interventions and advanced imaging techniques further enhance the therapeutic options. Future research must prioritize mechanistic insights and multidisciplinary collaboration to optimize outcomes for this increasingly prevalent condition.
